Cargando…
Topical retapamulin in the management of infected traumatic skin lesions
Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697516/ https://www.ncbi.nlm.nih.gov/pubmed/19436611 |
_version_ | 1782168332533760000 |
---|---|
author | Shawar, Ribhi Scangarella-Oman, Nicole Dalessandro, MaryBeth Breton, John Twynholm, Monique Li, Gang Garges, Harmony |
author_facet | Shawar, Ribhi Scangarella-Oman, Nicole Dalessandro, MaryBeth Breton, John Twynholm, Monique Li, Gang Garges, Harmony |
author_sort | Shawar, Ribhi |
collection | PubMed |
description | Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specific cross-resistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options. |
format | Text |
id | pubmed-2697516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26975162009-06-17 Topical retapamulin in the management of infected traumatic skin lesions Shawar, Ribhi Scangarella-Oman, Nicole Dalessandro, MaryBeth Breton, John Twynholm, Monique Li, Gang Garges, Harmony Ther Clin Risk Manag Review Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specific cross-resistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options. Dove Medical Press 2009 2009-03-26 /pmc/articles/PMC2697516/ /pubmed/19436611 Text en © 2009 Shawar et al, publisher and licensee Dove Medical Press Ltd. |
spellingShingle | Review Shawar, Ribhi Scangarella-Oman, Nicole Dalessandro, MaryBeth Breton, John Twynholm, Monique Li, Gang Garges, Harmony Topical retapamulin in the management of infected traumatic skin lesions |
title | Topical retapamulin in the management of infected traumatic skin lesions |
title_full | Topical retapamulin in the management of infected traumatic skin lesions |
title_fullStr | Topical retapamulin in the management of infected traumatic skin lesions |
title_full_unstemmed | Topical retapamulin in the management of infected traumatic skin lesions |
title_short | Topical retapamulin in the management of infected traumatic skin lesions |
title_sort | topical retapamulin in the management of infected traumatic skin lesions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697516/ https://www.ncbi.nlm.nih.gov/pubmed/19436611 |
work_keys_str_mv | AT shawarribhi topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT scangarellaomannicole topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT dalessandromarybeth topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT bretonjohn topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT twynholmmonique topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT ligang topicalretapamulininthemanagementofinfectedtraumaticskinlesions AT gargesharmony topicalretapamulininthemanagementofinfectedtraumaticskinlesions |